Even in resource-limited settings, it may prove cost-effective to repeat Xpert MTB/RIF testing for PLHIV with CD4 counts <100 cells/μL who are at the highest risk for both TB disease and TB-related early mortality. This evidence concerns the gene CD4 and tuberculosis.